Post-Autologous Immune Cell Therapy Quality of Life in Cancer Patients: A Retrospective Study
Abstract
Objective: Patients with advanced cancer are treated palliatively, with a focus on quality-of-life improvements through the amelioration of symptoms and functional status. This study aimed to evaluate the quality of life of cancer patients post-autologous immune cell therapy (ICT), as it is known for its ability to replace defective immune cells, which reduces cancer-related symptoms and may improve patient quality of life.
Meterial and Methods: The patients’ whole blood was processed to obtain activated immune cells. Treatment consisted of 6 autologous intravenous ICT infusions with an interval of 2 weeks. Patient quality of life was evaluated with the EORTC-QLQ-C30 questionnaire before and after 6 autologous ICT treatments.
Results: Quality of life score increased in global health status, physical functioning, role functioning, cognitive functioning, and social functioning. There was a reduction in scores on the symptom scales for fatigue and pain components.
Conclusion: Improvements in quality of life, function, and symptoms in cancer patients were observed after 6 autologous ICT treatments.
Keywords
Full Text:
PDFReferences
Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2024;74:229–63.
Rosen RD, Sapra A. TNM classification [monograph on the Internet]. Treasure Island (FL): StatPearls Publishing; 2025 [cited 2025]. Available from: https://www.ncbi.nlm.nih.gov/books/
Brierley J, Gospodarowicz M, O’Sulivan B. The principles of cancer staging. Ecancermedicalscience 2016;10:ed61. doi: 10.3332/ecancer.2016.ed61.
Kypriotakis G, Vidrine DJ, Francis LE, Rose JH. The longitudinal relationship between quality of life and survival in advanced stage cancer. Psychooncology 2016;25:225–31. doi: 10.1002/pon.3846.
Sahu M, Suryawanshi H. Immunotherapy. J Oral Maxillofac Pathol 2021;25:371. doi: 10.4103/0973-029X.325257.
Fragkiadakis GF, Spiliotopoulou M. Investigating the quality of life for cancer patients and estimating the cost of immunotherapy in selected cases. Cureus 2022;14:e32390. doi: 10.7759/cureus.32390.
Maziarz RT, Waller EK, Jaeger U, Fleury I, McGuirk J, Holte H, et al. Patient-reported long-term quality of life after tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma. Blood Adv 2020;4:629–37. doi: 10.1182/bloodadvances.2019001026.
Du N, Guo F, Wang Y, Cui J. NK Cell Therapy: a rising star in cancer treatment. Cancers (Basel) 2021;13:4129. doi: 10.3390/cancers13164129.
Canadian Agency for Drugs and Technologies in Health. Dostarlimab (Jemperli): CADTH Reimbursement Review: Therapeutic area: Endometrial cancer [monograph on the Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 [cited 2025]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK602691/
Cocks K, King MT, Velikova G, Martyn St-James M, Fayers PM, Brown JM. Evidence-based guidelines for determination of sample size and interpretation of the European Organisation For The Research And Treatment Of Cancer Quality Of Life Questionnaire Core 30. J Clin Oncol 2011;29:89–96. doi: 10.1200/JCO.2010.28.0107.
Kim HM, Lim J, Park S-K, Kang JS, Lee K, Lee CW, et al. Antitumor activity of cytokine-induced killer cells against human lung cancer. Int Immunopharmacol 2007;7:1802–7. doi: 10.1016/j.intimp.2007.08.016.
The European Organisation for Research and Treatment of Cancer. EORTC QLQ-C30 scoring manual. Brussels: European Organisation for Research and Treatment of Cancer; 2001.
Noviyani R, Tunas K, Indrayathi A, Budiana NG. Validity and Reliability of EORTC QLQ C-30 Questionnaire in Assessing Quality of Life of Gynecological Cancer Patients in Sanglah Hospital Denpasar. Indones J Clin Pharm 2016;5:106–14. doi: 10.15416/ijcp.2016.5.2.106.
Han J, Zhang B, Zheng S, Jiang Y, Zhang X, Mao K. The progress and prospects of immune cell therapy for the treatment of cancer. Cell Transplant 2024;33. doi: 10.1177/09636897241231892.
Fernandez SV, MacFarlane AW, Jillab M, Arisi MF, Yearley J, Annamalai L, et al. Immune phenotype of patients with stage IV metastatic inflammatory breast cancer. Breast Cancer Res 2020;22:134. doi: 10.1186/s13058-020-01371-x.
Ménétrier-Caux C, Ray-Coquard I, Blay J-Y, Caux C. Lymphopenia in cancer patients and its effects on response to immunotherapy: an opportunity for combination with Cytokines? J Immunother Cancer 2019;7:85. doi: 10.1186/s40425-019-0549-5.
Arruga F, Gyau BB, Iannello A, Vitale N, Vaisitti T, Deaglio S. Immune Response Dysfunction in Chronic Lymphocytic Leukemia: Dissecting Molecular Mechanisms and Microenvironmental Conditions. Int J Mol Sci 2020;21:1825. doi: 10.3390/ijms21051825.
Imran M, Al-Wassia R, Alkhayyat SS, Baig M, Al-Saati BA. Assessment of quality of life (QoL) in breast cancer patients by using EORTC QLQ-C30 and BR-23 questionnaires: a tertiary care center survey in the western region of Saudi Arabia. Ahmad A, editor. PLoS One 2019;14:e0219093. doi: 10.1371/journal.pone.0219093.
Snyder CF, Blackford AL, Sussman J, Bainbridge D, Howell D, Seow HY, et al. Identifying changes in scores on the EORTC-QLQ-C30 representing a change in patients’ supportive care needs. Qual Life Res 2015;24:1207–16. doi: 10.1007/s11136-014-0853-y.
Madu A, Ocheni S, Ibegbulam O, Madu K, Aguwa E. Pattern of CD4 T-lymphocyte values in Cancer patients on cytotoxic therapy. Ann Med Health Sci Res 2013;3:498. doi: 10.4103/2141-9248.122054.
Pan K, Guan X-X, Li Y-Q, Zhao J-J, Li J-J, Qiu H-J, et al. Clinical Activity of Adjuvant Cytokine-Induced Killer Cell Immunotherapy in Patients with Post-Mastectomy Triple-Negative Breast Cancer. Clin Cancer Res 2014;20:3003–11. doi: 10.1158/1078-0432.CCR-14-0082.
Gao X, Mi Y, Guo N, Xu H, Xu L, Gou X, et al. Cytokine-Induced Killer Cells As Pharmacological Tools for Cancer Immunotherapy. Front Immunol 2017;8:774. doi: 10.3389/fimmu.2017.00774.
Kornacker M, Moldenhauer G, Herbst M, Weilguni E, Tita-Nwa F, Harter C, et al. Cytokine-induced killer cells against autologous CLL: Direct cytotoxic effects and induction of immune accessory molecules by interferon-γ. Int J Cancer 2006;119:1377–82. doi: 10.1002/ijc.21994.
Zhang P, Zhang G, Wan X. Challenges and new technologies in adoptive cell therapy. J Hematol Oncol 2023;16:97. doi: 10.1186/s13045-023-01492-8.
Chen R, Johnson J, Rezazadeh A, Dudek AZ. Tumour-infiltrating lymphocyte therapy landscape: prospects and challenges. BMJ Oncol 2025;4:e000566. doi: 10.1136/bmjonc-2024-000566.
Refbacks
- There are currently no refbacks.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.